High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype

Table 2

Correlation of LTBP2 protein expression with clinical characteristics of CRC patients.

Feature		LTBP2			value
		Low or no expression	High expression
Total	204	146	58
Gender				3.559	0.059
Male	127	85 (66.9%)	42 (33.1%)
Female	77	61 (79.2%)	16 (20.8%)
Age				0.001	0.976
≤60	63	45 (71.4%)	18 (28.6%)
>60	141	101 (71.6%)	40 (28.4%)
Location				1.343	0.511
Right colon	35	23 (65.7%)	12 (34.3%)
Left colon	111	83 (74.8%)	28 (25.2%)
Rectum	58	40 (69.0%)	18 (31.0%)
Differentiation				0.095	0.954
Poor	4	3 (75.0%)	1 (25.0%)
Well and middle	194	139 (71.6%)	55 (28.4%)
Others^a	6	4 (66.7%)	2 (33.3%)
TNM stage				38.118	<0.001
0 and I	47	44 (93.6%)	3 (6.4%)
II	78	60 (76.9%)	18 (23.1%)
III	65	40 (61.5%)	25 (38.5%)
IV	14	2 (14.3%)	12 (85.7%)
T stage				15.953	<0.001
Tis, T1, and T2	54	50 (92.6%)	4 (7.4%)
T3, T4	150	96 (64.0%)	54 (36.0%)
N stage				20.443	<0.001
N0	128	104 (81.2%)	24 (18.8%)
N1a	40	26 (65.0%)	14 (35.0%)
N1b	20	10 (50.0%)	10 (50.0%)
N2a,b	16	6 (37.5%)	10 (62.5%)
M stage				24.24	<0.001
M0	190	144 (75.8%)	46 (24.2%)
M1	14	2 (14.3%)	12 (85.7%)
Preoperative CEA (ng/ml)				4.798	0.091
≤5	71	57 (80.3%)	14 (19.7%)
>5	78	50 (64.1%)	28 (35.9%)
Unknown	55	39 (70.9%)	16 (29.1%)

^aMucinous adenocarcinoma, 6 cases. .